Catalyst Event
Amgen Inc (AMGN) · Other
From KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index (KUSDV100P)
3/23/2026, 12:00:00 AM
Amgen announced on March 23, 2026, that its Phase 3 ROCKET-Outpost study for rocatinlimab, a treatment for atopic dermatitis, has been completed. The study evaluated the self-administration of the drug.
Korean Translation
2026년 3월 23일, 아토피 피부염 치료제 로카틴리맙(rocatinlimab)의 자가 투여를 평가하는 3상 ROCKET-Outpost 연구가 완료되었음을 발표함.
Related Recent Events
EOG Resources Inc. (EOG) · Earnings Release
EOG Resources First Quarter 2026 financial results release and conference call on May 6, 2026, as announced on March 24, 2026, scheduled. Low impact estimated as routine quarterly results typically result in <5% price movement.
5/6/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
First quarter 2026 earnings release scheduled for April 30, 2026. Medium importance is estimated based on typical price volatility during earnings announcements, and the release is scheduled.
4/30/2026, 12:00:00 AM
Conocophillips (COP) · Earnings Release
First-quarter 2026 earnings release and conference call scheduled.
4/30/2026, 12:00:00 AM
Lockheed Martin Corp (LMT) · Earnings Release
First quarter 2026 earnings release is scheduled.
4/28/2026, 12:00:00 AM
United Parcel Service Inc (UPS) · Earnings Release
Q1 2026 United Parcel Service, Inc. Earnings Conference Call, which typically drives >1% price volatility, is scheduled.
4/28/2026, 12:00:00 AM
SLB Ltd (SLB) · Earnings Release
Q1 2026 earnings release is scheduled for April 24, 2026; a low impact is estimated as the announcement is a routine calendar event, scheduled.
4/24/2026, 12:00:00 AM